1. Home
  2. XAIR vs SHPH Comparison

XAIR vs SHPH Comparison

Compare XAIR & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

HOLD

Current Price

$0.50

Market Cap

5.4M

Sector

Health Care

ML Signal

HOLD

Logo Shuttle Pharmaceuticals Holdings Inc.

SHPH

Shuttle Pharmaceuticals Holdings Inc.

HOLD

Current Price

$1.00

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XAIR
SHPH
Founded
2011
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4M
5.2M
IPO Year
2015
2022

Fundamental Metrics

Financial Performance
Metric
XAIR
SHPH
Price
$0.50
$1.00
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
336.8K
168.2K
Earning Date
06-16-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
62.09
N/A
EPS
N/A
N/A
Revenue
$3,705,000.00
N/A
Revenue This Year
$122.00
N/A
Revenue Next Year
$58.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
219.67
N/A
52 Week Low
$0.15
$0.12
52 Week High
$3.78
$5.59

Technical Indicators

Market Signals
Indicator
XAIR
SHPH
Relative Strength Index (RSI) 35.74 54.79
Support Level $0.43 $0.80
Resistance Level $0.82 $1.13
Average True Range (ATR) 0.07 0.13
MACD 0.00 0.03
Stochastic Oscillator 17.29 64.81

Price Performance

Historical Comparison
XAIR
SHPH

About XAIR Beyond Air Inc.

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

About SHPH Shuttle Pharmaceuticals Holdings Inc.

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.

Share on Social Networks: